SC
IRWD icon

Savant Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

Savant Capital’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,257
Closed -$133K – 1306
2024
Q1 		$133K Buy
+15,257
New +$185K ﹤0.01% 1061

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Savant Capital's IRWD Position: Q2 2024 in Review

Savant Capital sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2024, closing a stake of 15,257 shares — an estimated $133K sold.

Savant Capital first reported a position in IRWD in Q1 2024 and held it in 1 quarter. The position peaked at $133K in Q1 2024. 226 funds tracked by Wall St. Rank hold IRWD as of Q2 2024.

  • Savant Capital reported no remaining Ironwood Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Savant Capital sold 15,257 Ironwood Pharmaceuticals shares in Q2 2024, an estimated $133K.
  • Savant Capital first reported a position in Ironwood Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Savant Capital's Ironwood Pharmaceuticals position peaked at $133K in Q1 2024.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2024.

Based on Savant Capital's 13F filing for Q2 2024, filed 5 Aug 2024.